-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

Credit Suisse Initiates Coverage On NewAmsterdam Pharma with Outperform Rating, Announces Price Target of $21

Benzinga · 01/06/2023 08:01
Credit Suisse analyst Judah Frommer initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Outperform rating and announces Price Target of $21.